Coagulation Factor Changes Associated With Postpartum Hysterectomies
1 other identifier
observational
24
1 country
1
Brief Summary
The purpose of this study is to examine components of the coagulation system in women undergoing postpartum hysterectomy and to compare laboratory parameters of coagulation in these women to women at increased risk for a postpartum hysterectomy, but who do not have postpartum hemorrhage and a postpartum hysterectomy. During normal pregnancy, the hemostatic balance tips toward hypercoagulation. Non-obstetric surgical blood loss is associated with increased coagulation activity. We have observed that women undergoing a postpartum hysterectomy become hypocoagulable secondary to a consumptive coagulopathy and/or excessive fibrinolysis. This coagulopathy may lead to the administration of multiple blood products. Worldwide, postpartum hemorrhage is a leading cause of maternal death. Plasma levels of tissue plasminogen activator, urokinase plasminogen activator and their inhibitors increase during pregnancy. During labor and delivery activation of coagulation occurs with consumption of platelets, coagulation factors and inhibitors. Obstetric complications during delivery can excessively activate the coagulation system and disseminated intravascular coagulation may ensue. Current treatment for postpartum coagulopathy is non-specific and primarily consists of replacing blood components. If specific causes or markers of abnormal coagulation can be identified in women at risk, then it might be possible to target (with specific medications) specific abnormalities early in the process and decrease hemorrhage and the need for blood transfusions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2003
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2006
CompletedFirst Submitted
Initial submission to the registry
April 3, 2007
CompletedFirst Posted
Study publicly available on registry
April 5, 2007
CompletedResults Posted
Study results publicly available
February 20, 2012
CompletedApril 14, 2014
March 1, 2014
3 years
April 3, 2007
November 6, 2011
March 17, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Fibrinogen Level at 2 Hours After Delivery
Fibrinogen level decrease is a marker of consumptive coagulation which is is a pathological activation of coagulation (blood clotting) mechanisms that happens in response to a variety of diseases or stimulus. We hypothesized that women with excessive bleeding following delivery who require a hysterectomy are more likely to exhibit lower levels of fibrinogen and a consumptive coagulopathy than women following cesarean delivery who do not bleed.
2 hours after delivery
Secondary Outcomes (3)
Platelet Counts at 2 Hours After Delivery
2 hours after delivery
Plasminogen Levels 2 Hours After Delivery
2 hours after delivery
Antithrombin III Levels at 2 Hours Post Delivery
2 hours after delivery
Study Arms (2)
Postpartum hysterectomy
Women that require postpartum hysterectomy for post-delivery bleeding.
Cesarean delivery case controls
Women that deliver by cesarean that presented with risk factors for bleeding but did not require post delivery hysterectomy
Interventions
Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
Eligibility Criteria
Pregnant Women
You may qualify if:
- All women scheduled for a Cesarean-hysterectomy will be asked to enroll in the study, as well as the women with the following diagnoses, that puts them at increased risk for Cesarean hysterectomy: placenta previa, placenta accreta, vaginal trial of labor after previous Cesarean delivery.
You may not qualify if:
- Anyone who does not fit the above criteria.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Northwestern University
Chicago, Illinois, 60611, United States
Related Publications (4)
Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Effects of progressive blood loss on coagulation as measured by thrombelastography. Anesth Analg. 1987 Sep;66(9):856-63.
PMID: 3619091BACKGROUNDHellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125-30. doi: 10.1055/s-2003-38897.
PMID: 12709915BACKGROUNDLanir N, Aharon A, Brenner B. Procoagulant and anticoagulant mechanisms in human placenta. Semin Thromb Hemost. 2003 Apr;29(2):175-84. doi: 10.1055/s-2003-38833.
PMID: 12709921BACKGROUNDSaftlas AF, Olson DR, Atrash HK, Rochat R, Rowley D. National trends in the incidence of abruptio placentae, 1979-1987. Obstet Gynecol. 1991 Dec;78(6):1081-6.
PMID: 1945212BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Robert J McCarthy, Pharm D
- Organization
- Northwestern University Feinberg School of Medicine
Study Officials
- PRINCIPAL INVESTIGATOR
Cynthia A Wong, M.D.
Northwestern University
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Anesthesiology
Study Record Dates
First Submitted
April 3, 2007
First Posted
April 5, 2007
Study Start
December 1, 2003
Primary Completion
December 1, 2006
Study Completion
December 1, 2006
Last Updated
April 14, 2014
Results First Posted
February 20, 2012
Record last verified: 2014-03